Pharmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant, TNK-tPA, in Patients with Acute Myocardial Infarction

The rapid clearance of t-PA from plasma requires administration by intravenous (I.V.) infusion. A slower clearing, fibrin-specific rt-PA variant may allow single intravenous bolus administration, thereby simplifying dosing. This study was designed to characterize the pharmacokinetics of the slower clearing, fibrin-specific tissue-plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction (AMI) following a single I.V. bolus injection. Single I.V. bolus doses of 5 to 50 mg of TNK-tPA were studied in an open-label, multicenter, dose escalation study. A total of 113 AMI patients were enrolled. Blood sampling for pharmacokinetics was conducted in eighty-two patients (72 men, 10 women), with 5 to 27 patients per dose. TNK-tPA was administered as an I.V. bolus over 5-10 s. Following I.V. bolus administration, there was a biphasic elimination of TNK-tPA from plasma. The initial phase had a mean half-life that ranged from 11 +/- 5 to 20 +/- 6 min and was followed by a terminal phase with a mean half-life that ranged from 41 +/- 16 to 138 +/- 84 min. Mean TNK-tPA plasma clearance was 125 +/- 25 - 216 +/- 98 ml/min, and the initial volume of distribution was 4.3 +/- 2 - 8.4 +/- 6 1. A decrease in TNK-tPA plasma clearance with increasing TNK-tPA dose was noted. In addition, women and patients with lower body weight or older age had a slower plasma clearance. In conclusion, TNK-tPA has a slower plasma clearance in patients with AMI than that reported for rt-PA, allowing administration as a single I.V. bolus.

[1]  E. Braunwald,et al.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.

[2]  B. Keyt,et al.  New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. , 1995, Circulation.

[3]  K. Gough,et al.  Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .

[4]  C. Cannon,et al.  Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.

[5]  J. Mehta,et al.  Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. , 1994, The American journal of cardiology.

[6]  B. Keyt,et al.  A Long‐Half‐life and Fibrin‐Specific Form of Tissue Plasminogen Activator in Rabbit Models of Embolic Stroke and Peripheral Bleeding , 1994, Stroke.

[7]  B. Keyt,et al.  Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog , 1994, Thrombosis and Haemostasis.

[8]  D. Botstein,et al.  A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Gusto Angiographic Investigators.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[10]  B. Keyt,et al.  A Slow Clearing, Fibrin-Specific, PAI-1 Resistant Variant of t-PA (T103N, KHRR 296-299 AAAA) , 1993, Thrombosis and Haemostasis.

[11]  B. Keyt,et al.  A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen , 1993, Thrombosis and Haemostasis.

[12]  D. Lipkin,et al.  Effectiveness and safety of a single intravenous Bolus injection of tissue-type plasminogen activator in acute myocardial infarction , 1992 .

[13]  J. Wójcik,et al.  Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. , 1992, Journal of the American College of Cardiology.

[14]  U. Tebbe,et al.  Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.

[15]  K. Strein,et al.  Pharmacokinetics of the Novel Recombinant Plasminogen Activator BM 06.022 in Rats, Dogs, and Non-human Primates , 1992 .

[16]  C. Wilson,et al.  Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction. , 1991, The American journal of cardiology.

[17]  F. Dunn,et al.  A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. , 1991, British heart journal.

[18]  B. Sobel,et al.  Thrombolysis and Myocardial Infarction , 1991 .

[19]  E. Braunwald.  Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator. , 1989, Journal of the American College of Cardiology.

[20]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[21]  E. Seifried,et al.  Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. , 1989, The American journal of cardiology.

[22]  E. Seifried,et al.  Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction , 1989, Thrombosis and Haemostasis.

[23]  G. Larsen,et al.  Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. , 1989, Blood.

[24]  M. Simoons,et al.  Thrombolytic therapy in acute myocardial infarction. , 1989, Annual review of medicine.

[25]  B. Smedsrød,et al.  Tissue Plasminogen Activator is Endocytosed by Mannose and Galactose Receptors of Rat Liver Cells , 1988, Thrombosis and Haemostasis.

[26]  E. Topol,et al.  Monitoring of Hemostasis Parameters During Coronary Thrombolysis with Recombinant Tissue-Type Plasminogen Activator , 1988, Thrombosis and Haemostasis.

[27]  B. Reavy,et al.  A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. , 1988, The Journal of biological chemistry.

[28]  M. Gottwik,et al.  Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). , 1988, Journal of the American College of Cardiology.

[29]  G. Larsen,et al.  Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. , 1988, Blood.

[30]  E. Seifried,et al.  Comparison of Specific Antibody, D-Phe-Pro-Arg-CH2Cl and Aprotinin for Prevention of In Vitro Effects of Recombinant Tissue-Type Plasminogen Activator on Haemostasis Parameters , 1987, Thrombosis and Haemostasis.

[31]  D. Collen,et al.  Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody. , 1987, Blood.

[32]  M. Mohler,et al.  D-Phe-Pro-Arg-Chloromethylketone: Its Potential Use in Inhibiting the Formation of In Vitro Artifacts in Blood Collected During Tissue-Type Plasminogen Activator Thrombolytic Therapy , 1986, Thrombosis and Haemostasis.

[33]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[34]  D. Collen,et al.  Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA , 1985, Thrombosis and Haemostasis.

[35]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[36]  P. Wallén,et al.  An Enzyme Linked Immunosorbent Assay for Determination of Tissue Plasminogen Activator Applied to Patients with Thromboembolic Disease , 1983, Thrombosis and Haemostasis.

[37]  Leon Shargel,et al.  Applied biopharmaceutics and pharmacokinetics , 1980 .